9. Bristol-Myers Squibb Company (NYSE:BMY)
Number of Hedge Fund Holders — 74
New Cancer Medicines Must Grow Faster Than the Patent Clock Ticks
Bristol-Myers Squibb Company (NYSE: BMY) delivered a stronger commercial update on October 29, reporting third-quarter revenue of approximately $13.1 billion, up 7% from a year earlier. Its Growth Portfolio generated $7.7 billion, an increase of 12%, giving investors measurable evidence that newer products are contributing to the business. Management raised its full-year revenue outlook to $49.75 billion–$50.25 billion and updated its non-GAAP earnings guidance to $6.35–$6.55 per share. Those figures make the investment discussion more concrete than a pipeline-only story, although acquisitions, research charges, and the transition away from older products continue to complicate the earnings picture.
The oncology pipeline added another meaningful development on October 12. Investigational radiopharmaceutical RYZ101 met the primary endpoint of progression-free survival in the Phase 3 ACTION-1 trial. The study involved patients with certain advanced gastroenteropancreatic neuroendocrine tumors whose disease had progressed after earlier lutetium-based radiopharmaceutical treatment. This is a specific opportunity in a difficult treatment setting, rather than a broad claim about gastrointestinal cancers. The company also highlighted the approval of Zenbexus, a first-in-class CELMoD treatment for multiple myeloma, in its quarterly update. Together, these developments broaden the potential contribution from its cancer treatment portfolio.
The central investment question remains whether newer medicines can become large enough, quickly enough, to offset pressure on established franchises. Chief Executive Officer Christopher Boerner described “another quarter of double-digit growth in our Growth Portfolio,” but investors still need to distinguish revenue expansion from earnings growth. Third-quarter non-GAAP earnings of $1.35 per share included a negative $0.58 net impact from acquired research charges and licensing income. For investors assessing pharmaceutical stocks, the appeal lies in an existing commercial platform supporting additional oncology opportunities. The challenge is ensuring that tomorrow’s growth arrives before patent expirations present today’s business with a smaller invoice.
Ranking rationale — Bristol-Myers Squibb Company (NYSE: BMY) ranks ninth with 74 hedge fund holders. Its established cancer franchises, growing newer-product portfolio, and radiopharmaceutical progress support the investment case, while patent exposure and the cost of replenishing its pipeline remain central considerations.
